{"id":"human-plasma-derived-antithrombin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antithrombin is a serine protease inhibitor that binds to and inactivates thrombin (Factor IIa) and other activated coagulation factors (particularly Factor Xa). By neutralizing these key enzymes in the coagulation cascade, antithrombin prevents the formation of blood clots and is used therapeutically in patients with antithrombin deficiency or thrombotic disorders.","oneSentence":"Antithrombin is a natural anticoagulant protein that inhibits blood clotting factors to prevent thrombosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:02.037Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Antithrombin deficiency (congenital or acquired)"},{"name":"Thromboembolism prevention and treatment in high-risk patients"}]},"trialDetails":[{"nctId":"NCT06096116","phase":"PHASE3","title":"Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-08-21","conditions":"Acquired Antithrombin Deficiency","enrollment":120},{"nctId":"NCT01698567","phase":"PHASE1","title":"Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2012-07","conditions":"Congenital Heart Disease","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Human plasma derived antithrombin","genericName":"Human plasma derived antithrombin","companyName":"Octapharma","companyId":"octapharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antithrombin is a natural anticoagulant protein that inhibits blood clotting factors to prevent thrombosis. Used for Antithrombin deficiency (congenital or acquired), Thromboembolism prevention and treatment in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}